AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25675682 — intervention group
Group type: COMPARATOR
Intervention: JR
Number of subjects: 20
Study 23497109 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring system (non-invasive system monitoring vital signs including oxygen saturation, heart rate, near-body temperature, overall physical activity)
Number of subjects: 99
Study 23497109 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring system
Number of subjects: 99
Study 23497109 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 99
Study 20825622 — intervention group
Group type: EXPERIMENTAL
Intervention: Short waiting time (SWT ≤ 3 months)
Number of subjects: 438
Study 20825622 — intervention group
Group type: COMPARATOR
Intervention: Nonfixed waiting time (NFWT > 3 months)
Number of subjects: 438
Study 18300748 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRIUS eligible group (n=296)
Number of subjects: 838
Study 18300748 — intervention group
Group type: COMPARATOR
Intervention: SIRIUS ineligible group (n=542)
Number of subjects: 838
Study 15142001 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of creatine (20 g per day for 6 days) and sodium bicarbonate (0.3 g per kg body weight 2 hours before swims)
Number of subjects: 16
Study 15142001 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of creatine and sodium bicarbonate
Number of subjects: 16
Study 15142001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11676942 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue PCI (TIMI 0 or 1 flow at 90 minutes)
Number of subjects: 1938
Study 11676942 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive PCI (TIMI 2 or 3 flow at 90 minutes)
Number of subjects: 1938
Study 11676942 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed PCI (performed >150 minutes after symptom onset)
Number of subjects: 1938
Study 11676942 — intervention group
Group type: COMPARATOR
Intervention: Successful thrombolysis (TIMI 3 flow at 90 minutes) without revascularization
Number of subjects: 1938
Study 9570429 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) tablet
Number of subjects: 205
Study 9570429 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) spray
Number of subjects: 205
Study 9570429 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) spray
Number of subjects: 205
Study 7932931 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal suction followed by tracheal suction
Number of subjects: 49
Study 7932931 — intervention group
Group type: COMPARATOR
Intervention: Oropharyngeal suction
Number of subjects: 49
Study 2438638 — intervention group
Group type: EXPERIMENTAL
Intervention: IM or oral iron treatments
Number of subjects: 191
Study 2438638 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 191
Study 30322357 — intervention group
Group type: EXPERIMENTAL
Intervention: Interarytenoid assessment protocol
Number of subjects: 30
Study 30322357 — intervention group
Group type: COMPARATOR
Intervention: Comparison with operating surgeon
Number of subjects: 30
Study 29174940 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate-rectum hydrogel spacer
Number of subjects: 0
Study 29174940 — intervention group
Group type: COMPARATOR
Intervention: Control (no spacer)
Number of subjects: 0
Study 26701964 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 150
Study 26701964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 25176223 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocet (M) 60 mg/m2 i.v. plus cyclophosphamide (C) 600 mg/m2 on Day 1 of a 21‐day cycle (Arm A)
Number of subjects: 233
Study 25176223 — intervention group
Group type: COMPARATOR
Intervention: Myocet (M) 50 mg/m2 plus vinorelbine (V) 25 mg/m2 i.v. on Day 1 and V 60 mg/m2 orally on Day 8 on a 21‐day cycle (Arm B)
Number of subjects: 233
Study 23174844 — intervention group
Group type: EXPERIMENTAL
Intervention: Needles
Number of subjects: 75
Study 23174844 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeds
Number of subjects: 75
Study 23174844 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study 21163010 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual anti-collagen membranes
Number of subjects: 24
Study 21163010 — intervention group
Group type: COMPARATOR
Intervention: Atelocollagen membranes
Number of subjects: 24
Study 17426001 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive epidural analgesia combined with postoperative epidural analgesia
Number of subjects: 66
Study 17426001 — intervention group
Group type: COMPARATOR
Intervention: Postoperative epidural analgesia alone
Number of subjects: 66
Study 17426001 — intervention group
Group type: COMPARATOR
Intervention: Postoperative intravenous analgesia
Number of subjects: 66
Study 16279895 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with 2 mg/kg body weight of Photosan-3, light activation performed 48 hours after intravenous application
Number of subjects: 32
Study 16279895 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with endoprostheses, no PDT
Number of subjects: 32
Study 16279895 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 32
Study 16279895 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 11280104 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study 11280104 — intervention group
Group type: COMPARATOR
Intervention: Nonselective NSAIDs
Number of subjects: 0
Study 11280104 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs with concomitant GPAs
Number of subjects: 0
Study 9208360 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic verapamil (120 mg twice daily for 14 days)
Number of subjects: 8
Study 9208360 — intervention group
Group type: COMPARATOR
Intervention: Brand-name verapamil (120 mg twice daily for 14 days)
Number of subjects: 8
Study 9208360 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic verapamil
Number of subjects: 8
Study 9208360 — intervention group
Group type: COMPARATOR
Intervention: Brand-name verapamil
Number of subjects: 8
Study 9208360 — intervention group
Group type: EXPERIMENTAL
Intervention: Both verapamil products
Number of subjects: 8
Study 7525541 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 3678219 — intervention group
Group type: EXPERIMENTAL
Intervention: Gp I (n = 22) with rest intervals of 5, 15, 45, 135, 405, and 1215 seconds
Number of subjects: 39
Study 3678219 — intervention group
Group type: COMPARATOR
Intervention: Gp II (n = 17) with rest intervals of 10, 30, 90, 270, 810, and 2550 seconds
Number of subjects: 39
Study 31990936 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagliptin (200 mg twice daily)
Number of subjects: 24
Study 31990936 — intervention group
Group type: COMPARATOR
Intervention: Control (previous treatment schedules)
Number of subjects: 24
Study 30961415 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y ibritumomab tiuxetan radioimmunotherapy (Y90)
Number of subjects: 46
Study 27096722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250‐μg metered‐dose inhaler
Number of subjects: 22
Study 27096722 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo metered‐dose inhaler
Number of subjects: 22
Study 24996569 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadofosveset
Number of subjects: 11
Study 24996569 — intervention group
Group type: COMPARATOR
Intervention: Gadobenate dimeglumine
Number of subjects: 11
Study 24196464 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one therapy
Number of subjects: 249
Study 24196464 — intervention group
Group type: COMPARATOR
Intervention: Group-based therapy
Number of subjects: 249
Study 24196464 — intervention group
Group type: COMPARATOR
Intervention: Monitored home program
Number of subjects: 249
Study 21703806 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with previous or simultaneous carotid endarterectomy (CEA)
Number of subjects: 185
Study 21703806 — intervention group
Group type: COMPARATOR
Intervention: CABG followed by carotid endarterectomy (CEA)
Number of subjects: 185
Study 19506003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation with controlled breathing (6 breaths/min for 10 minutes twice daily during the eight-week treatment period)
Number of subjects: 44
Study 19506003 — intervention group
Group type: COMPARATOR
Intervention: Usual cardiac rehabilitation
Number of subjects: 44
Study 16400508 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Health Enhancement Support System (CHESS)
Number of subjects: 8
Study 15277159 — intervention group
Group type: EXPERIMENTAL
Intervention: High zinc intake (12 mg/d)
Number of subjects: 16
Study 15277159 — intervention group
Group type: COMPARATOR
Intervention: Low zinc intake (4 mg/d)
Number of subjects: 16
Study 10930963 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 1600 microg twice daily
Number of subjects: 9
Study 10930963 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1000 microg twice daily
Number of subjects: 9
Study 10930963 — intervention group
Group type: COMPARATOR
Intervention: BUD and FP (comparison)
Number of subjects: 9
Study 10930963 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD
Number of subjects: 9
Study 10930963 — intervention group
Group type: EXPERIMENTAL
Intervention: FP
Number of subjects: 9
Study 9024229 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant DNA‐derived preparations of human GH
Number of subjects: 121
Study 8070986 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contact Therapeutic Touch (NCTT)
Number of subjects: 0
Study 30782712 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture intervention (one treatment for five consecutive weeks)
Number of subjects: 70
Study 30782712 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture intervention
Number of subjects: 70
Study 30782712 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment offered after 6 weeks)
Number of subjects: 70
Study 29641571 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium and coenzyme Q10 supplementation for four years
Number of subjects: 443
Study 29641571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study 27001965 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus Aspirin
Number of subjects: 2573
Study 27001965 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2573
Study 25216762 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib and capecitabine (L-CAP)
Number of subjects: 197
Study 22753087 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega 3/6 supplementation (Equazen eye q)
Number of subjects: 75
Study 22753087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 19921305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT), 10 sessions
Number of subjects: 21
Study 19921305 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group), 12-week waiting period
Number of subjects: 21
Study 18844819 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep therapy (multi-component intervention including sleep restriction, cognitive behavioral therapy, bright-light therapy, structured physical activity, and body temperature manipulations)
Number of subjects: 38
Study 18844819 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (healthy well-sleeping age-matched subjects)
Number of subjects: 38
Study 16192592 — intervention group
Group type: EXPERIMENTAL
Intervention: classical CMF (cyclophosphamide, methotrexate, and fluorouracil)
Number of subjects: 1475
Study 16192592 — intervention group
Group type: EXPERIMENTAL
Intervention: ECS present
Number of subjects: 1475
Study 16192592 — intervention group
Group type: COMPARATOR
Intervention: ECS absent
Number of subjects: 1475
Study 12874586 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatine-coated Dacron (GEL-D) grafts
Number of subjects: 149
Study 12874586 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-coated Dacron (COL-D) grafts
Number of subjects: 149
Study 12874586 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretch PTFE grafts
Number of subjects: 149
Study 12874586 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 149
Study 10583440 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (30 ppm, 30 min)
Number of subjects: 15
Study 10583440 — intervention group
Group type: COMPARATOR
Intervention: Control gas
Number of subjects: 15
Study 10583440 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (640 mg x 1 orally)
Number of subjects: 15
Study 8913542 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 25 mg
Number of subjects: 0
Study 8913542 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 0
Study 8913542 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Number of subjects: 0
Study 8913542 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 200 mg
Number of subjects: 0
Study 8913542 — intervention group
Group type: COMPARATOR
Intervention: Losartan 100 mg (multiple dosing)
Number of subjects: 0
Study 8913542 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multiple dosing)
Number of subjects: 0
Study 8913542 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (all doses)
Number of subjects: 0
Study 1649497 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 40
Study 1649497 — intervention group
Group type: COMPARATOR
Intervention: Oral conjugated equine estrogens (CEE)
Number of subjects: 40
Study 6613808 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil, 320 mg per day
Number of subjects: 11
Study 6613808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31542766 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational leaflet on seat belt use
Number of subjects: 2216
Study 31542766 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational leaflet)
Number of subjects: 2216
Study 27364640 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5-year screening interval
Number of subjects: 7915
Study 26866518 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (300, 150 mg)
Number of subjects: 1144
Study 26866518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1144
Study 25529851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular dexmedetomidine (1 µg·kg‐1)
Number of subjects: 40
Study 25529851 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.02 mg·kg‐1)
Number of subjects: 40
Study 22986757 — intervention group
Group type: EXPERIMENTAL
Intervention: Let's Read program delivered at 4, 12, 18, and 42 months during universal well-child care visits
Number of subjects: 630
Study 19571157 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified wheat flakes (MWF)
Number of subjects: 11
Study 19571157 — intervention group
Group type: COMPARATOR
Intervention: Standard wheat flakes (SWF)
Number of subjects: 11
Study 19571157 — intervention group
Group type: COMPARATOR
Intervention: White-wheat bread (WWB)
Number of subjects: 11
Study 17353101 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg twice daily)
Number of subjects: 225
Study 17353101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 17353101 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 225
Study 15084616 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Tipifarnib (200 mg bid orally continuously; gemcitabine at 1,000 mg/m² intravenously weekly x 7 for 8 weeks, then weekly x 3 every 4 weeks)
Number of subjects: 688
Study 15084616 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine + Placebo (gemcitabine at 1,000 mg/m² intravenously weekly x 7 for 8 weeks, then weekly x 3 every 4 weeks)
Number of subjects: 688
Study 15084616 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Tipifarnib
Number of subjects: 688
Study 15084616 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine + Placebo
Number of subjects: 688
Study 11347792 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of urinary incontinence (UI) with primary care provider
Number of subjects: 49
Study 11347792 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of urinary incontinence as a problem
Number of subjects: 49
Study 11347792 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of urinary incontinence as a normal part of aging
Number of subjects: 49
Study 11347792 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to discussing urinary incontinence
Number of subjects: 49
Study 11347792 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of urinary incontinence episodes
Number of subjects: 49
Study 9684793 — intervention group
Group type: EXPERIMENTAL
Intervention: INR values obtained using 8 different thromboplastin reagents in patients without LA (n = 47)
Number of subjects: 90
Study 9684793 — intervention group
Group type: EXPERIMENTAL
Intervention: INR values obtained using 8 different thromboplastin reagents in patients with LA (n = 43)
Number of subjects: 90
Study 9684793 — intervention group
Group type: EXPERIMENTAL
Intervention: INR values obtained with recombinant thromboplastin Innovin in patients with LA
Number of subjects: 90
Study 8053507 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty alone (n = 23)
Number of subjects: 57
Study 8053507 — intervention group
Group type: COMPARATOR
Intervention: Supplemental atherectomy
Number of subjects: 57
Study 8053507 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI increase by 0.3 or more
Number of subjects: 57
Study 8053507 — intervention group
Group type: COMPARATOR
Intervention: ABI increase less than or equal to 0.1
Number of subjects: 57
Study 8053507 — intervention group
Group type: EXPERIMENTAL
Intervention: Short occlusions (less than or equal to 5 cm, n = 8)
Number of subjects: 57
Study 8053507 — intervention group
Group type: COMPARATOR
Intervention: Long occlusions (greater than 25 cm, n = 16)
Number of subjects: 57
Study 2722598 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluosol-DA 20% infusion (8 mL/Kg, 6 infusions) + 100% oxygen breathing
Number of subjects: 46
Study 2722598 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluosol-DA 20% infusion (various dosages and infusions) + 100% oxygen breathing
Number of subjects: 46
Study 2722598 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluosol-DA 20% infusion
Number of subjects: 46
Study 30594631 — intervention group
Group type: COMPARATOR
Intervention: Control (EX0) - ExciTE F adhesive
Number of subjects: 45
Study 30594631 — intervention group
Group type: EXPERIMENTAL
Intervention: EX2 - 2 wt% proanthocyanidins added to ExciTE F
Number of subjects: 45
Study 30594631 — intervention group
Group type: EXPERIMENTAL
Intervention: EX5 - 5 wt% proanthocyanidins added to ExciTE F
Number of subjects: 45
Study 28595464 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex activation therapy (BAT) for 16 months
Number of subjects: 100
Study 28595464 — intervention group
Group type: COMPARATOR
Intervention: Continuous pharmacotherapy (BAT off) for 8 months followed by BAT for 8 months
Number of subjects: 100
Study 28595464 — intervention group
Group type: EXPERIMENTAL
Intervention: BAT for 3 months after 16 months
Number of subjects: 100
Study 25281894 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (3 mg Bid)
Number of subjects: 30
Study 25281894 — intervention group
Group type: COMPARATOR
Intervention: Systemic methylprednisolone (40 mg Qd for three days, then 8 mg Bid)
Number of subjects: 30
Study 23698078 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Group (TG) - 2-week landing training, 3 times per week, 6 sessions
Number of subjects: 20
Study 23698078 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - no intervention
Number of subjects: 20
Study 21442135 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly 1‐hr training session including aerobic interval training, circuit training, and whole body vibration
Number of subjects: 8
Study 21442135 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 8
Study 18639327 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER (4 mg once daily)
Number of subjects: 850
Study 18639327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 850
Study 17469502 — intervention group
Group type: EXPERIMENTAL
Intervention: Elmex toothpaste (amine fluoride, 0.125% F) without rinsing
Number of subjects: 120
Study 17469502 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridol toothpaste (amine fluoride, stannous(II) fluoride, 0.14% F) without rinsing
Number of subjects: 120
Study 17469502 — intervention group
Group type: COMPARATOR
Intervention: Both toothpastes with rinsing
Number of subjects: 120
Study 17469502 — intervention group
Group type: EXPERIMENTAL
Intervention: Both toothpastes without rinsing
Number of subjects: 120
Study 12601286 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 298
Study 12601286 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 298
Study 12601286 — intervention group
Group type: COMPARATOR
Intervention: PTCA and CABG combined
Number of subjects: 298
Study 10999783 — intervention group
Group type: EXPERIMENTAL
Intervention: Low isoflavone diet (1.00 mg/kg body wt/day, averaging 65 mg/day)
Number of subjects: 31
Study 10999783 — intervention group
Group type: EXPERIMENTAL
Intervention: High isoflavone diet (2.01 mg/kg body wt/day, averaging 130 mg/day)
Number of subjects: 31
Study 10999783 — intervention group
Group type: EXPERIMENTAL
Intervention: Low and high isoflavone diets
Number of subjects: 31
Study 10999783 — intervention group
Group type: COMPARATOR
Intervention: Control diet (0.13 mg/kg body wt/day, averaging 8 mg/day)
Number of subjects: 31
Study 8852910 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b alone (10 million units/m2, three times weekly for 1 year)
Number of subjects: 31
Study 8852910 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b after prednisone priming (10 million units/m2, three times weekly for 1 year)
Number of subjects: 31
Study 8852910 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment, n=9)
Number of subjects: 31